

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**COMMON SPLENDOR INTERNATIONAL
HEALTH INDUSTRY GROUP LIMITED**

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO
CAPITAL CONTRIBUTION IN AND ACQUISITION OF
100% EQUITY INTEREST IN
FENGSHUO BIO MEDICAL TECH AND
51% EQUITY INTEREST IN
GUANGDONG KELV BIO MEDICAL TECH COMPANY LIMITED
AND
CAPITAL CONTRIBUTION TO OBTAIN 28%
EQUITY INTEREST IN FENGYUAN HUAKE BIO TECH**

Reference is made to the announcements dated 23 November 2015 and 30 November 2018 (the “**Announcements**”), 28 March 2018, 6 September 2018, 6 November 2018, 19 December 2018 and 1 November 2019 (the “**November Announcement**”) of Common Splendor International Health Industry Group Limited (the “**Company**”). Unless the context otherwise states, capitalised terms used in this announcement have the same meanings as those defined in the Announcements and the November Announcement.

ACTUAL 2018 NET PROFIT

Based on the audited financial statements of Target Company No. 1 for FY2018, the Actual 2018 Net Profit amounted to approximately RMB22.7 million, which is higher than the 2018 Guarantee Net Profit of RMB20 million. Accordingly, given the 2018 Guarantee Net Profit has been met, no equity interest in Target Company No. 1 held by the Vendor has to be transferred to the Purchaser due to any shortfall in the 2018 Guarantee Net Profit under the Supplemental Agreement.

By Order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 15 November 2019

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang, Mr. Hou Kai Wen and Mr. Wong Kin Man as non-executive Directors; and Mr. Mai Yang Guang, Mr. Lam Chi Wing and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.